The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy by Pastor-Idoate, S. (Salvador) et al.
The T309G MDM2 Gene Polymorphism Is a Novel Risk
Factor for Proliferative Vitreoretinopathy
Salvador Pastor-Idoate1,2, Irene Rodrı´guez-Herna´ndez2,3, Jimena Rojas1, Itziar Ferna´ndez1,
Marı´a T. Garcı´a-Gutie´rrez1, Jose´ M. Ruiz-Moreno4, Amandio Rocha-Sousa5, Yashin Ramkissoon6,
Steven Harsum6, Robert E. MacLaren6,7, David Charteris6, Jan C. VanMeurs8, Rogelio Gonza´lez-
Sarmiento2,3*, Jose´ C. Pastor1*, on behalf of the Genetics on PVR Study Group"
1 Instituto de Oftalmobiologı´a (IOBA-Retina Group), University of Valladolid, Valladolid, Spain, 2Unidad de Medicina Molecular, Departamento de Medicina, University of
Salamanca, Salamanca, Spain, 3 Instituto de Investigacio´n Biome´dica de Salamanca (IBSAL) and Instituto de Biologı´a Molecular y Celular del Ca´ncer (IBMCC), University of
Salamanca–CSIC-SACYL, Salamanca, Spain, 4University of Castilla La Mancha, Vissum, Albacete, Spain, 5Department of Sense Organs, Medical School, University of Porto,
Hospital San Joa˜o, Porto, Portugal, 6Moorfields Eye Hospital, National Institute of Health Research (NIHR), Biomedical Research Centre, London, United Kingdom,
7Nuffield Laboratory of Ophthalmology, University of Oxford, John Radcliffe Hospital Oxford, United Kingdom, 8 Rotterdam Eye Hospital, Erasmus Medical Center,
University of Rotterdam, The Netherlands
Abstract
Proliferative vitreoretinopathy (PVR) is still the major cause of failure in retinal detachment (RD) surgery. It is believed that
down-regulation in the p53 pathway could be an important key in PVR pathogenesis. The purpose was to evaluate the
impact of T309G MDM2 polymorphism (rs2279744) in PVR. Distribution of T309G MDM2 genotypes among European
subjects undergoing RD surgery was evaluated. Proportions of genotypes between subsamples from different countries
were analyzed. Also, a genetic interaction between rs2279744 in MDM2 and rs1042522 in p53 gene was analyzed. Significant
differences were observed comparing MDM2 genotype frequencies at position 309 of intron 1 between cases (GG: 21.6%,
TG: 54.5%, TT: 23.8%) and controls (GG: 7.3%, TG: 43.9%, TT: 48.7%). The proportions of genotypes between sub-samples
from different countries showed a significant difference. Distribution of GG genotype revealed differences in Spain (35.1–
53.0)/(22.6–32.9), Portugal (39.0–74.4)/(21.4–38.9), Netherlands (40.6–66.3)/(25.3–38.8) and UK (37.5–62.4)/(23.3–34.2). The
OR of G carriers in the global sample was 5.9 (95% CI: 3.2 to 11.2). The OR of G carriers from Spain and Portugal was 5.4 (95%
CI: 2.2–12.7), whereas in the UK and the Netherlands was 7.3 (95% CI: 2.8–19.1). Results indicate that the G allele of
rs2279744 is associated with a higher risk of developing PVR in patients undergoing a RD surgery. Further studies are
necessary to understand the role of this SNP in the development of PVR.
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Introduction
Proliferative vitreoretinopathy (PVR) is still the major cause of
failure in retinal detachment (RD) surgery [1], affecting 5% to
10% of RD and accounting for approximately 75% of all primary
failures after RD surgery [1,2]. It is considered an abnormal
wound-healing process induced by a retinal break allowing the
posterior escape of retinal pigment epithelium cells (RPE) into a
pro-inflammatory vitreous environment [3–7]. In any RD, the
blood-ocular barrier breaks down, possibly due to disruption of the
photoreceptor-RPE cell interface, then inflammatory cells are
recruited increasing the inflammatory mediators production into
the vitreous cavity [8–10]. Growth factors and cytokines in the
vitreous cavity seem to be responsible for RPE migration,
metaplasia and proliferation [11–13], which can result in the
development of epi and subretinal membranes which are some of
the characteristic clinical features of PVR. Tangential contraction
of the membranes leads to reduced internal diameter of the retina
and subsequent tension which rapidly develops into RD once a
break allows ingress of subretinal fluid [14–16]. Some of those
growth factors are also responsible of the glial cell hypertrophy
causing important changes inside of the retinal tissue and inducing
a shortening of the neuroretina, the most severe form of PVR [17].
Although PVR was identified in 1983 as an independent entity
[18], and many efforts have been made for treating and preventing
it during these years, there is neither current available medical
treatment nor prophylaxis. Nowadays, treatment for PVR
consisted of surgery, with an anatomically successful of 60% to
80% in the less severe cases and below of 40% in the most severe
cases [19,20]. Surgical procedures have a significant cost [21],
involve the risk of recurrence [22], and above all have poor
functional results [23–26]. Besides the efforts to identify nonsur-
gical approaches to treat PVR, they have not had success [27–29].
Most research has to date attempted to identify the clinical risk
factors related to the development of PVR after RD; however,
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these clinical factors do not completely explain the probability of
its onset [30]. Since PVR is a cell-based inflammatory response,
like other inflammatory responses, genetic susceptibility may have
an important role. In previous studies, we have partially described
the contribution of the genetic component to PVR [31–34]. Single
nucleotide polymorphisms (SNPs) have important implications for
human genetic diseases and they may help to identify the genetic
predisposition of certain diseases, either as a causative or
protective factor.
Besides the role of many inflammatory mediators in the
development of PVR and RD [35], previous studies have shown
increased level of p53 and the activation of various cell death
mechanisms after RD [36,37]. Also it has been reported that
photoreceptor death after RD and subsequent visual loss could be
caused by apoptosis or other cell death pathways, such as
programmed necrosis, when the pathways for apoptosis were
inhibited by some drugs [38–40].
In normal unstressed cells, p53 is a very unstable protein with a
half-life ranging from 5 to 30 min, which is present at very low
levels owing to continuous degradation largely mediated by
murine double min 2 protein (MDM2) [41,42]. Importantly,
MDM2 itself is the product of a p53-inducible gene [42]. Thus, the
two molecules are linked to each other through an autoregulatory
negative feedback loop aimed at maintaining low cellular p53
levels in the absence of stress and limiting the duration and severity
of various p53-mediated biological responses after a non-lethal
stress response. Conversely, a hallmark of many cellular stress
pathways such as DNA damage, hypoxia, ischemia, telomere
shortening, and oncogene activation is the rapid stabilization of
p53 via a block of its degradation [41].
Recently, it has been reported that the levels of p53 expression
could be a checkpoint in the development of RD and PVR, and
how its local increase in the vitreous by using inhibitors of MDM2,
seem to be a promising approach as a prophylaxis in experimental
RD and also in experimental PVR [43].
The MDM2 gene is a key negative regulator of p53 and in
humans seems to have two promoter-enhancer regions that
regulate the levels of MDM2 mRNA. The first promoter is 59 to
the first exon and likely regulates the basal level of MDM2 in a
nonstressed cell. The second promoter region is in the first intron
and this region increases the expression of MDM2 after a p53
response [41,42]. This intron is composed of 524 nucleotides with
the T.G SNP at nucleotide 309. The G/G variant increases the
binding affinity of the transcriptional activator Sp1 resulting in
high levels of MDM2 protein; formation of transcriptionally
inactive p53-MDM2 complexes and a consequent decreased
activity of the p53 pathway [44,45].
Thus, the purpose of this study was to analyze the distribution of
the MDM2 T309G polymorphism in the first intron of MDM2
gene, in a consecutive sample of patients undergoing primary
rhegmatogenous RD surgery with and without PVR, recruited
from several European clinical centres through the project named
Retina 4.
Materials and Methods
Ethics Statement
The study was approved by the local Ethics Committees of
Instituto de Oftalmobiologı´a (IOBA-Retina Group) (Valladolid,
Spain), Hospital San Joa˜o (Porto, Portugal), Moorfields Eye
Hospital (London, United Kingdom) and Rotterdam Eye Hospital
(Rotterdam, Netherlands) and followed the tenets of the Decla-
ration of Helsinki. All patients received written informed consent
before entering in the study.
Design and study population
DNA samples from the Retina 4 project were analyzed. This
work is made up in two steps: first, a candidate gene association
study in the T309G polymorphism (rs2279744) located into the
MDM2 gene was carried out. Second, the interaction between this
polymorphism and the p53 codon 72 polymorphism (rs10425229)
was investigated.
Candidate gene association study
The association study was carried out among 555 patients from
7 centers: 3 in Spain, 2 in Portugal, 1 in the United Kingdom (UK)
and 1 in Netherlands. The global sample was divided in sub-
samples according to the country for the analysis. This study was
carried out in two phases. In the first one, sub-samples from Spain
and Portugal were analyzed. After significant results were found in
this first cohort, subsequent samples from the UK and the
Netherlands were analyzed (second phase). To compare if there
were differences regarding geographical localization in the odds
ratio analysis, Spain and Portugal were considered as Southern
countries and the UK and the Netherlands as Northern countries.
Genotypic and allelic frequencies were also compared between
cases and controls in the global series.
Detailed explanation of the exclusion and inclusion criteria for
classification of patients has been provided in a previous
publication [33]. In brief, all participants were patients with a
primary rhegmatogenous RD who underwent surgery. Exclusion
criteria were: age under 16 years old; traumatic, tractional,
exudative or iatrogenic RD; RD secondary to macular hole or
giant retinal tears (larger than 3 clock hours) and pre-operative
PVR grade higher than B. Those who did not develop clinical
signs of PVR after 3 months of follow-up were included in the
control group. Those who developed PVR grade C1 or higher,
according to Machemer classification, were included as cases.
Genetic interaction
Interaction between the MDM2 polymorphism (rs2279744) and
one SNP (rs1042522) located in the p53 gene previously identified
by our group as significantly associated to PVR [33] was
investigated. Samples used for analyzing p53 polymorphism were
same samples than for the MDM2 SNP. Carriers of Pro variant of
rs1042522 and G variant of rs2279744, were analyzed in the
global sample and in the sub-samples from different countries.
Genotyping
Genotyping of the MDM2 T309G polymorphism was per-
formed at the Molecular Medicine Unit at the University of
Salamanca, (Salamanca, Spain) blinded to the clinical status of
patients, using the PCR-RFLP (Polymerase Chain Reaction-
Restriction Fragment Length Polymorphism) technique [46,47].
The MDM2 T309G polymorphism was detected after ampli-
fication of genomic DNA with the forward primer 5’-
GAGGTCTCCGCGGGAGTTC-3’ and the reverse primer 5’-
CTGCCCACTGAACCGGC-3’. MDM2 intron 1 was amplified
within a 155 pb DNA fragment that was digested with the
restriction endonuclease MspA1I (New England Biolabs, Inc.).
PCR reactions were performed in a 50-ml reaction mixture
containing 100–200 ng of target DNA, 20 pmol of each primer,
2.5 mM MgCl2, 50 mM of each dNTP and 1.25 U of HotMaster
Taq DNA polymerase (5 Prime GmbH, Hamburg, Germany).
DNA was amplified with the following steps: an initial 5-min
denaturation at 94uC, followed by 35 cycles of 94uC for 30 s, 61uC
for 30 s, 72uC for 30 s, and a final elongation at 72uC for 10 min.
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The resulting fragments were separated on 3.5% agarose gel
(Figure 1) and the ethidium bromide–stained fragments were
analyzed under a UV source, using the Kodak Digital Science ID
image analysis system.
The polymerase chain reaction fragments, containing T and G
alleles, after digestion migrated as 2 fragments of 101 and 54 bp
for G homozygotes (GG), 1 fragments of 155 for T homozygotes
(TT), and 3 fragments of 157, 101 and 54 bp for heterozygotes
(TG).
Statistical analysis
The quality of data was evaluated in control sub-samples by
Hardy-Weinberg equilibrium using the Chi-square test. Genotypic
frequencies were estimated in each sub-sample. The proportions of
genotypes and the G homozygote groups between sub-samples
were analyzed. Also, the genotypic and allelic frequencies were
compared between cases and control in the global sample and in
the sub-samples from different countries. In the genetic interac-
tion, patients carrying the Pro variant of rs1042522 and the G
variant of rs2279744 were analyzed in the global sample and in
the sub-samples from different countries.
Association was investigated using the Chi-Square and the
Fisher’s tests. The strength of association was measured using
Odds Ratio (OR) and 95% confidence intervals (CI). Two
inheritance models were considered: co-dominant model that
allows every genotype to give a different and non-additive risk, and
recessive model in which two copies of the G allele are necessary to
change the risk. The Akaike Information Criterion (AIC) [48] was
used in order to choose the inheritance model that best fitted the
data. The statistical analyses were performed by using SPSS 16.0
for Macintosh and R software (Software Foundation’s GNU
project) [49].
In order to adjust p-values for multiple comparisons a
permutation test was performed. We used 1000 random shuffles
of the case/control labels to get the correct distribution of test
statistics under the no-association hypothesis. The ranking of the
real test statistic among the shuffled test statistics gives the adjusted
p-values.
Results
Candidate gene association study
A total of 555 peripheral DNA blood samples including 134
cases and 421 controls were analyzed (203 from Spain (36.57%),
68 from Portugal (12.25%), 121 from Netherlands (21.80%) and
163 from the UK (29.36%). Regarding clinical information some
significant associations were observed. The control group was
significantly older than cases (p,0.0001) with the difference
between median of 6 years (95% CI: 3.39-8.31). A significant
association in patients with history of PVR in the fellow eye was
found in the cases group. Also status of the lens was determined
because aphakia has been related to a higher incidence of PVR
[5,30] (Table 1). There were no significant associations with sex,
race, affected eye or history of phakic status. There were no
differences regarding the geographical localization or centre where
the patients came from.
There were no failures for the genotyping process, with a global
call rate of 96.21%. Additionally, in order to ensure accuracy of
allele-specific results, a randomized selection of samples PCRs
were assessed by an independent researcher unaware of the
patients’ status. All control sub-samples verified the Hardy-
Weinberg equilibrium.
Phase I: genotypic distribution of MDM2 T309G polymor-
phism in Spain and Portugal.
The frequencies of the genotypes in each country are shown in
Table 2. The comparison of proportions of genotypes between
sub-samples showed a significant difference (p,0.05) between
cases and controls. Also a significant difference (p,0.05) in G
homozygote carriers between sub-samples in the control group (CI
G homozygote: Spain (22.6–32.9), Portugal (21.4–38.9)) and the
cases group (CI G homozygote: Spain (35.1–53.0), Portugal (39.0–
74.4)) was found.
The odds ratio of G carriers from Spain and Portugal together
considering a co-dominant model (T/T, T/G and G/G) (AIC =
307.7 vs 311.4 of a recessive model) was 5.4 (95% CI: 2.3 to 12.7)
(Table 3).
Phase II: genotypic distribution of MDM2 T309G polymor-
phism in UK and the Netherlands.
The frequencies of the genotypes in patients from the UK and
the Netherlands are shown in Table 1. Also, the distribution of
genotypes between subjects from those countries showed statistical
differences. When G homozygote carriers between cases and
controls were analyzed a significant difference in both groups of
patients was found in control (CI of G homozygote: Netherlands
(25.3–38.8), UK (23.3–34.2)) and cases (CI of G homozygote:
Netherlands (40.6–66.2), UK (25.3–38.8)). Also, differences were
found in the odds ratio distribution of homozygous carriers of the
G variant in patients from the UK and the Netherlands together
considering a co-dominant model (AIC = 277.8 vs 288.4 of a
recessive model) (odds ratio 7.3 (95% CI: 2.8 to 19.1) (Table 3).
When all samples were grouped, (Table 4) significant differences
in the distribution of genotypes between the controls and cases
(p,0.05) were found. Also homozygous carriers of the G variant
were more frequent in PVR cases (CI: 42.9–54.8) than in controls
(CI: 26.2–32.4). The odds ratio of the G variant in the global
sample using a co-dominat model (AIC = 584.1 versus 598.7 of a
recessive model) was 5.9 (CI: 3.2 to 11.2) (Table 3).
Figure 1. PCR-RFLP to determine MDM2 SNP309 polymorphism. MDM2 SNP309 T allele is not cleaved by MspA1I endonuclease and
generates a single fragment of 155 bp. The MDM2 SNP309 G allele is cleaved by MspA1I and generates two small fragments of 101 and 54 bp. The
MDM2 SNP309 heterozygote displays three fragments of 155, 101 and 54 bp.
doi:10.1371/journal.pone.0082283.g001
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Allelic frequencies comparison
Significant differences in the analysis of the allelic frequencies
were found between cases and controls in Spain and Portugal and
between cases and controls in UK and Netherlands (Table 2)
Genetic interaction
When the global sample was analyzed, 16 patients (2.91%) who
meet both p53 and MDM2 genotypes (Pro variant plus G variant
carriers) (8 patients from Spain and Portugal, and 8 patients from
the UK and the Netherlands) were found. A significant difference
in the distribution of genotypes between the controls and cases
(p,0.0001) was found in the global sample. The odds ratio of Pro
and G carriers in global sample was 10.19 (95% CI: 3.2 to 31.9)
(Table 5).
Significant differences in the distribution of genotypes between
the controls and cases from Spain and Portugal together
(p = 0.0006) and UK and Netherlands together (p,0.01) were
found. The odds ratio of Pro and G carriers from the UK and the
Netherlands together was 6.5 (95% CI: 1.5 to 28.2), whereas, the
odds ratio of Pro and G carriers from Spain and Portugal together
was 20.4 (95% CI: 2.4 to 169.5) (Table 5).
Discussion
Our results show that Spanish and Portuguese carriers of the
homozygous G SNP at position 309 have a 5.4 -fold increased risk
of PVR after RD than those that carry the T allele. This
observation was confirmed also in Dutch and British population
(odds ratio 7.3 (95% CI: 2.8 to 19.1). Interestingly, when Pro and
G restriction site carriers in the global sample were analyzed, an
additional effect (odds ratio 10.19 (95% CI: 3.2 to 31.9) was found.
But both polymorphisms were only present in 16 patients out of
555 patients. Although significant results were also found in the
latter analysis, we consider that 16 may be too small a sample to
draw absolute conclusions and further studies may be necessary in
order to know the absolute potential risk of this restriction site
association.
PVR is considered a multifactorial disease [31,32] and may be
the result of interaction between genetic and environmental factors
[30–32]. The difficulty in identifying of patients at risk of
developing PVR after RD by clinical characteristics [30] justifies
our efforts to elucidate any genetic components [30–32]. A simple
genetic test might identify higher risk patients before RD surgery,
which might then be modified in a more personalized form.
Table 1. Clinical characteristics of the whole sample.
Characteristics Controls, n RD (%) Cases, n PVR (%) Total P-value*
Race 0,064
-Caucasian 370 (73.56%) 133 (26.44%) 503
-Hispano-American 6 (46.15%) 7 (53.85%) 13
-Hindu 7 (58.33%) 5 (41.67%) 12
-Arabic-North-African 6 (100%) 0 6
-Sub-Saharan 2 (50%) 2 (50%) 4
-Asian 3 (60%) 2 (40%) 5
-Unknown 12
Sex 0,362
-Male 248 (71.26%) 100 (25.37%) 348
-Female 135 (75%) 45 (31.42%) 180
-Unknown 27
Status of the lens (Phakia) 0,233
-Yes 250 (74.63%) 85 (25.37%) 335
-No 131 (68.58%) 59 (31.42%) 190
-Unknown 30
RD in fellow eye 0,528
-Yes 32 (76.19%) 10 (23.81%) 42
-No 355 (68.58%) 136 (31.42%) 491
-Unknown 22
PVR in fellow eye 0,005(*)
-Yes 0 5 (100%) 5
-No 141 (26.70%) 387 (73.30%) 528
-Unknown 22
Geographical location 0,171
-Northern countries (UK+Netherlands) 224 (78.87%) 60 (22.2%) 284
-Southern countries (Spain+Portugal) 197 (72.7%) 74 (27.3%) 271
RD: Retinal detachment; PVR: Proliferative vitreoretinopathy.
*p-value: Chi-squared or Fishers exact test in the statistical analysis of clinical characteristics of the whole sample of the global sample. (*) A significant association in
patients with history of PVR in the fellow eye was found in the cases group.
doi:10.1371/journal.pone.0082283.t001
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Apoptosis is critically important during various developmental
processes, it is necessary to rid the body of pathogen-invaded cells
and also is involved in the removal of inflammatory cells and the
evolution of granulation tissue into scar tissue [50]. Moreover,
inappropriate apoptosis is an important factor in many human
pathologic conditions including neurodegenerative diseases, ische-
mic damage, autoimmune disorders and many types of cancer. In
addition, it has been reported that a deregulation of apoptosis
during wound healing can lead to pathologic forms of healing such
as excessive scarring and fibrosis [50].
As mentioned, PVR is considered an abnormal wound-healing
process induced by the production of a retinal break and vitreal
escape of RPE cells into an appropriate intraocular pro-
inflammatory environment [3–7]. It is characterized by several
intraretinal and extraretinal changes. One of the commonest is the
extracellular matrix (ECM) formation, produced by activated-
cytokines RPE cells (RPE cells transdifferentiate into mesenchymal
like a-smooth muscle actin cells) in the vitreous cavity [51,52].
This series of events culminates in the formation of a retina-
associated membrane over and/or behind the neuroretina, which
further contracts and thereby causes recurrent and tractional RD.
Nevertheless the most severe changes are induced inside the retina
by stimulating a reactive gliosis that causes a shortening of the
retina preventing its surgical reattachment [17]. Some of these
activating cytokines like transforming growth factor-b (TGFb), and
tumor necrosis factor a (TNFa), have been previously reported by
our group in association with PVR [30–32].
Current studies have highlighted the involvement of extrinsic
and intrinsic pathways of apoptosis in retinal cells after RD, and
also, the existence of other pathways, such as programmed
necrosis, when apoptosis are inhibited [40]. In addition, a
proteomic study of human vitreous samples of RD and PVR has
indicated that p53 could be involved in PVR process [53].
An association between p53 Arg72Pro polymorphism and PVR
has been recently reported by our group [33]. According to our
results, carriers of the Pro allele of the p53 gene, which are
Table 3. Models of inheritance in the global sample.
Model Genotype Controls Cases OR* CI 95% P-value AIC*
Corrected P-
value
Co-dominant T/T 205 (48.7%) 32 (24.0%) 1.00 2.0374e-08 584.1 0,00091
T/G 185 (43.9%) 73 (54.4%) 2.53 (1.59–4.01)
G/G 31 (7.4%) 29 (21.6%) 5.99 (3.20–11.24)
Dominant T/T 205 (48.7%) 32 (24.0%) 1.00 - 2.1790e-07 590.7 0,00091
T/G-G/G 216 (51.3%) 102 (76.0%) 3.03 (1.95–4.70)
Recessive T/T-T/G 390 (92.6%) 105 (78.4%) 1.00 - 1.4218e-05 598.7 0,00091
G/G 31 (7.4%) 29 (21.6%) 3.47 (2.00–6,02)
Over-dominant T/T-G/G 236 (56.1%) 61 (45.6%) 1.00 - 3.3371e-02 613.0 0,03191
T/G 185 (43.9%) 73 (54.4%) 1.53 (1.03–2.26)
Spain+Portugal T/T 99 (50.3%) 21 (28.4%) 1.00 - 0.0003 307.7 0,00191
T/G 84 (42.6%) 37 (50.0%) 2.08 (1.13–3.82)
G/G 14 (7.1%) 16 (21.6%) 5.44 (2.30–12.7)
Netherlands+UK T/T 106 (47.3%) 11 (18.3%) 1.00 - 2.6566e-05 277.8 0,00091
T/G 101 (45.1%) 36 (60.0%) 3.43 (1.66–7.11)
G/G 17 (7.6%) 13 (21.7%) 7.30 (2.80–19.01)
OR* (odds ratio).
AIC*(Akaike Information Criterion); The AIC is a measure of the relative goodness of fit of a statistical model. It can generally be used for the identification of an optimum
model in a class of competing models.
Given a set of candidate models for the data, the preferred model is the one with the minimum AIC value.
1Permutation test for multiple comparison adjustment.
Results of odds ratio using a co-dominant model for Spain plus Portugal and Netherlands plus United Kingdom (UK).
doi:10.1371/journal.pone.0082283.t003
Table 4. Distribution of MDM2 T309G polymorphism in the whole sample.
Genotypes T/T T/G G/G Total CI 95%*
P-value Fishers
test
Corrected P-
value OR2 CI OR 95%2
Cases 32 (23.9%) 73 (54.5%) 29 (21.6%)* 134 (100%) (42.9–54.8)* 1.6738e-08 0.00091 2.3 (1.73–3.05)2
Controls 205 (48.7%) 185 (43.9%) 31 (7.4%) 421 (100%) (26.2–32.4)* - -
Total 237 258 60 555
1. Permutation test for multiple comparison adjustment.
2. OR. (Odds ratio).
*Analysis of G homozygote carriers between case/control group.
Fishers test.
doi:10.1371/journal.pone.0082283.t004
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associated with a decrease in apoptotic function of p53, have
higher risk of PVR after RD. Furthermore it has been reported
that suppression of p53 expression might be a necessary event in
the development of RD and PVR, and maintaining levels of p53
with agents such as Nutlin-3, which prevents the interaction
between p53 and MDM2, might be effective in the prophylaxis of
RD and also PVR vitreous-induced contraction [43].
The MDM2 T309G polymorphism affects binding of transcrip-
tion factor Sp1 and is associated with an increased expression of
the MDM2 mRNA and attenuation of the p53 pathway
[41,42,46,47]. Interestingly, the elevated levels of MDM2 do not
reduce the levels of p53 in non-stressed cells and the blockage of
p53 binding to MDM2, using inhibitors of MDM2, promotes
apoptosis [54].
Also, it has been reported that in contrast to other retinal cell
types, the RPE cells are resistant to apoptosis, to TNFA and
oxidative stress, which trigger apoptosis in wide range of cells
[55,56]. These factors, at normal range are generally ineffective in
this cell type, however, it has also been reported that the use of
inhibitors of MDM2 produces an increase of expression of
proapoptotic targets capable of overcoming this inherent RPE
resistance to apoptosis [54].
The MDM2 T309G polymorphism has been associated to
several cancers [44–47] and also to inflammatory processes [57].
Moreover, the association with other polymorphisms of p53 (i.e.
p53 codon 72 polymorphism) increases the risk of development of
several tumors [45,46].
Results of this work suggest that carriers of the G allele of the
MDM2 gene, associated with a decrease in apoptotic function of
p53, have higher risk of PVR after RD. We can speculate that the
reduction in the levels of apoptosis in retinal cells may activates
other cell death pathways, like programmed necrosis, which would
increase the intraocular inflammation after RD, thus generating a
cascade of tissue responses that generate and amplify the hostile
microenvironment in which activated RPE can trans-differentiate.
It is also possible that the decline in the levels of p53 is a crucial
checkpoint in RD and PVR, and the recently developed ocular
formulation of Nutlin-3, which can be administered by sub-
conjunctival injection [58], could be an effective approach to
achieve a prophylaxis in PVR disease.
This study had some limitations. One important issue in an
association study is the sample size [59]. Probably, unlike other
association studies, our sample is too small and the power sample is
not enough to draw absolute conclusions, nevertheless, the sample
collection to achieve greater power would be an extremely
challenging for a low prevalence condition such as PVR. Cases
were younger than controls and this could be considered a
confounding factor. However, this difference was only of 6 year,
which makes unlikely that this responds to a certain genetic profile.
It is important to point out that functional polymorphisms are
considered of interest because they allow us to shed light on the
molecular basis of different pathologies. They also could be targets
in the development of new therapeutic strategies. In this case-
controlled study, we have identified one SNP within the MDM2
gene that shows a strong association with PVR across several
groups. Although we have carried out the study in two phases
these findings must be interpreted with caution until these results
are confirmed with further replication studies in order to confirm
its association, because one of the major pitfalls of genetic
association studies are the false positives [59,60].
In summary, this study indicates that the p53 pathway could be
implicated as a significant risk factor for PVR after RD and also it
highlights the role of these SNPs (rs1042522 and rs2279744) as
possible markers of PVR risk.
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